.Pharmacolibrary.Drugs.ATC.B.B01AC22

Information

Prasugrel is an oral antiplatelet agent used for the prevention of atherothrombotic events in patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI). It is a thienopyridine class inhibitor of the P2Y12 ADP platelet receptor. Prasugrel is approved and used in clinical practice for patients at risk of thrombotic cardiovascular events.

Pharmacokinetics

Pharmacokinetic parameters reported in healthy adult subjects following single oral administration of prasugrel 10 mg.

References

1. Jeon, HS, et al., & Lim, HS (2015). Pharmacokinetics and pharmacodynamics of ticagrelor and prasugrel in healthy male Korean volunteers. Clinical therapeutics 37(3) 563–573. DOI:10.1016/j.clinthera.2015.01.010 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25697420

2. Small, DS, et al., & Salazar, DE (2010). Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel. Clinical pharmacokinetics 49(12) 777–798. DOI:10.2165/11537820-000000000-00000 PUBMED:https://pubmed.ncbi.nlm.nih.gov/21053990

3. Jakubowski, JA, et al., & Angiolillo, DJ (2017). The Rationale for and Clinical Pharmacology of Prasugrel 5 mg. American journal of cardiovascular drugs : drugs, devices, and other interventions 17(2) 109–121. DOI:10.1007/s40256-016-0202-3 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27854064

Revisions

• 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)